Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery

Int J Nanomedicine. 2024 Aug 17:19:8437-8461. doi: 10.2147/IJN.S477652. eCollection 2024.

Abstract

Data published in 2020 by the International Agency for Research on Cancer (IARC) of the World Health Organization show that breast cancer (BC) has become the most common cancer globally, affecting more than 2 million women each year. The complex tumor microenvironment, drug resistance, metastasis, and poor prognosis constitute the primary challenges in the current diagnosis and treatment of BC. Magnetic iron oxide nanoparticles (MIONPs) have emerged as a promising nanoplatform for diagnostic tumor imaging as well as therapeutic drug-targeted delivery due to their unique physicochemical properties. The extensive surface engineering has given rise to multifunctionalized MIONPs. In this review, the latest advancements in surface modification strategies of MIONPs over the past five years are summarized and categorized as constrast agents and drug delivery platforms. Additionally, the remaining challenges and future prospects of MIONPs-based targeted delivery are discussed.

Keywords: Inorganic Nanomaterials; Nanopreparations; Organic Nanomaterials; Surface Engineering; Targeted Delivery.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / drug therapy
  • Drug Delivery Systems / methods
  • Female
  • Humans
  • Magnetic Iron Oxide Nanoparticles* / chemistry
  • Magnetite Nanoparticles / chemistry
  • Magnetite Nanoparticles / therapeutic use
  • Surface Properties
  • Tumor Microenvironment / drug effects

Substances

  • Antineoplastic Agents
  • Magnetite Nanoparticles

Grants and funding

This work was supported by the National Key R&D Program of China (International Programs & Strategic Innovative Programs, Grant No.2023YFE0112200); Key Program of International (Regional) Cooperative Research Projects of the National Natural Science Foundation of China (Grant No.82020108033); General Program of Natural Science Foundation of China (Grant No.82274255); International (Regional) Cooperation and Exchange Program of National Natural Science Foundation of China (Grant No.82211540013,82411530061); Natural Science Foundation of Guangdong Province (Grant No.2023A1515220221); International Joint Research Center for Anti-tumor Nanomedicine Innovation and Application (Grant No.2023A0505090002); Foundation of Zhongshan Hospital of Traditional Chinese Medicine (Grant No.YN2024A001, YN2024A004); The Fifth National Traditional Chinese Medicine Excellent Talents Training Program (2022).